99% Purity Fondaparinux Sodium Powder API Fondaparinux Sodium Pharmaceutical Intermediate Fondaparinux Sodium

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Fondaparinux Sodium
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Fondaparinux Sodium
• Name: Fondaparinux Sodium Powder
• Appearance: White or Almost White Powder
• Color: White or Almost White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Medicine
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 114870-03-0
• Mf: C31h45n3na10o49s8+2
• MW: 1730.1
• Melting Point: >209 C (DEC.)
• Storage Condition: 2-8 C
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

99% Purity Fondaparinux Sodium Powder API Fondaparinux Sodium Pharmaceutical Intermediate Fondaparinux Sodium

 

Product Description

Product Details

Product Name	Fondaparinux Sodium
CAS No.	114870-03-0
MF	C31H45N3Na10O49S8+2
MW	1730.1
Appearance and shape	White or almost white powder

Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein thrombosis which may lead to pulmonary embolism following major orthopaedic surgery. Fondaparinux is the first of a new class of antithrombic agents distinct from low molecular weight heparin (LMWH) and heparin. This entirely synthetic molecule is a copy of the heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin action. Fondaparinux does not display significant effects on coagulation tests (such as activated partial thromboplastin time and prothrombin time), does not bind to platelet factor 4 or promote heparin-induced thrombocytopenia. In phase III studies, fondaparinux significantly reduced the incidence of thromboembolism following orthopedic surgery, with an overall risk reduction of 50% in comparison to the LMWH, enoxaparin. Following subcutaneous administration, fondaparinux has a nearly complete bioavailability, a rapid onset of action, a prolonged half-life (17.2 h) enabling once daily dosing and is not metabolized preceeding renal excretion. The drug appears to be generally safe, with haemoragic complications either comparable to or higher than those for LMWH.

Application & Function

Function
Fondaparinux sodium is a new antithrombotic drug approved by FDA after heparin and low molecular heparin for the treatment and prevention of arterial thrombosis. Sulforaphane sodium is a synthetic specific activation of factor Xa inhibitor, the mechanism of action is to selectively bind to the A petri n factor, so that the AITn neutralizes the chemicalbook activated factor Xa to enhance the role of about 30 times, thus interrupting the coagulation waterfall reaction to inhibit thrombin generation and thrombosis progress Sulforaphane sodium has no direct effect on thrombin, but by inhibiting It is estimated that for every 1 molecule of factor Xa inhibition, 50 molecules of thrombin production can be prevented.
Application
1. Fondaparinux sodium has been used to test its neutralizing effect towards enterovirus D68-947 infection. It may be used in ultraviolet photodissociation (UVPD) measurements.
2. Synthetic pentasaccharide corresponding to the anti-thrombin binding site of heparin. Anti-thrombotic.

Specification